QIMR Berghofer researchers have discovered a potential new cancer immunotherapy target that involves switching off a regulatory cell to stop tumours growing and spreading.
The study findings have been published today in Cancer Discovery, a journal of the American Association for Cancer Research.
Senior researcher and head of QIMR Berghofer’s Cancer Immunoregulation and Immunotherapy Laboratory, Associate Professor Michele Teng, said in future the discovery could potentially help treat patients with cancers where other current immunotherapies have not worked.
“Our work on mice shows for the first time that many tumours display the molecule MR1 on their cell surface, and when it’s present, this molecule turns on an important regulatory cell that prevents the body’s own immune system from fighting the cancer,” Associate Professor Teng said.
“We found if a type of regulatory cell called MAIT (mucosal-associated invariant T) cells are turned on, they stop immune or white blood cells known as T and NK cells from attacking and killing off tumour cells.
“The cancer is effectively creating its own defence mechanism to evade immune attack and survive. The display of MR1 activates the MAIT cells, which in turn switch off cancer-fighting T and NK cells.
“While other regulatory cells of the immune system are known to stop T and NK cells from killing tumour cells, this is the first time it’s been shown that these regulatory MAIT cells can do this job.”
Associate Professor Teng said her team found that by giving mice an antibody that blocked MR1, this stopped the MAIT cells from becoming activated, and the T and NK cells could respond, slowing cancer growth and stopping it spreading.
“This work demonstrates that antibodies that block MR1 could in future be an effective new immunotherapy,” Associate Professor Teng said.
“It probably won’t work on every cancer, but it looks like it could be effective in treating cancers that can display the MR1 molecule. It also means this display of MR1 could be used to screen which patients would respond to this immunotherapy.
“We now need to replicate this research in humans.”
Associate Professor Teng said while the research was at a very early stage and required more work, it was promising.
“The next step is to try to understand what kind of human tumours display MR1 as a protective mechanism, which would then help us identify which tumours would respond best to MR1-blocking immunotherapy,” she said.
“Immunotherapies have been effectively used to treat more than 15 different cancer types but the proportion of patients that respond for each cancer can differ.
“In patients with advanced melanoma for example, current approved immunotherapies work in about 50 per cent of cases, but half do not respond, and that’s why we need to find new therapies.”
Learn more: POTENTIAL NEW CANCER TREATMENT A STEP CLOSER
Go deeper with Bing News on:
- Cancer treatment using a common cold virus offers hope to patientson April 10, 2021 at 12:49 pm
The results of the Phase 1 study, led by a researcher at NYU Langone Health and its Perlmutter Cancer Center, were announced on Friday, adding to the growing body of research into oncolytic viruses.
- Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting ...on April 10, 2021 at 10:32 am
Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional ...
- UAB-developed viral immunotherapy for pediatric brain tumors shows promiseon April 10, 2021 at 5:55 am
G207, an immunotherapy derived from a modified herpes virus is well tolerated in children with gliomas, and shows signs of clinical effectiveness Brain tumors are the most common solid tumor in ...
- Personalized Cancer Vaccine Guided by Mount Sinai Computations Is Safe, Shows Potential Benefit Against Multiple Tumor Typeson April 10, 2021 at 5:40 am
A personalized cancer vaccine developed with the help of a Mount Sinai computational platform raised no safety concerns and showed potential benefit in patients with different cancers, including lung ...
- Resistance to Immunotherapy in Patients with Urothelial Bladder Cancer Is Traced to Specific Sets of Immune Cellson April 9, 2021 at 9:18 pm
Sets of genes associated with resistance to immunotherapy in patients with metastatic urothelial cancer of the bladder have been identified and validated by researchers at Mount Sinai. In a study ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Level of chromosomal abnormality in non-small cell lung cancer may predict response to immunotherapyon April 10, 2021 at 4:36 am
Dana-Farber researchers find patients whose tumors have low aneuploidy levels often have better outcomes following treatment with immune ...
- Level of chromosomal abnormality in lung cancer may predict immunotherapy responseon April 9, 2021 at 9:00 pm
Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than ...
- The next generation of immunotherapy? Innate Pharma targets NK cellson April 9, 2021 at 4:29 am
Marseille-based company Innate Pharma is on a mission to develop cancer immunotherapies that take advantage of the body’s innate immune system.
- With new data, Merck could be first to bring immunotherapy to early kidney canceron April 8, 2021 at 9:11 am
Immunotherapy has quickly become a mainstay in the treatment ... The only approved treatment in the adjuvant setting is Sutent, an enzyme-blocking drug from Pfizer, but that could be on the verge of ...
- Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapyon April 7, 2021 at 5:00 am
Immutep was one of the Benzinga Biotech Small Cap Conference held virtually on March 24 & 25, 2021. The information contained in this article in no way represents investment advice or opinion on ...